Together, the present findings suggest that ZDHHC3 plays an essential oncogenic role in pancreatic cancer and propose the combination therapies of 2-BP and PD-1/PD-L1 blockade agents to facilitate checkpoint immunotherapy in pancreatic cancer. Here, PDCD1 is linked to familial pancreatic carcinoma.